Cancer-associated mutations in the IRF4 DNA-binding domain confer no disadvantage in DNA-binding affinity and may increase transcriptional activity
Tatum, N.J., Scott, R., Doody, G.M., Hickson, I., Jennings, C., Martin, M.P., Tooze, R.M., Tucker, J.A., Wittner, A., Wang, L.Z., Wright, E.K., Wedge, S.R., Noble, M.E.M.To be published.